General Considerations on Clinical Trials of Hemophilia Medicines
Hemophilia is an orphan disease associated with deficiency or complete lack of certain blood coagulation factors due to mutation of genes encoding their synthesis. Patients with hemophilia need continuous replacement therapy with coagulation factor products which are produced by recombinant DNA tech...
Saved in:
| Main Authors: | Zh. I. Avdeeva, A. A. Soldatov, V. P. Bondarev, V. A. Merkulov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2020-03-01
|
| Series: | Биопрепараты: Профилактика, диагностика, лечение |
| Subjects: | |
| Online Access: | https://www.biopreparations.ru/jour/article/view/251 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitor development in nonsevere hemophilia: data from the European Haemophilia Safety Surveillance (EUHASS) registry
by: Kathelijn Fischer, et al.
Published: (2025-05-01) -
Retrospective analysis of hemophilia B in Turkey: identifying main characteristics and treatment options
by: Bülent Zülfikar, et al.
Published: (2024-10-01) -
Hemophilic Arthropathy—Pathophysiology and Advances in Treatment
by: Katarina Kovač, et al.
Published: (2025-04-01) -
RENAL ALLOGENEIC TRANSPLANTATION IN PATIENT WITH HAEMOPHILIA B
by: N. V. Purlo, et al.
Published: (2014-12-01) -
Extravascular factor IX after gene therapy in hemophilia B, does it matter?
by: Quentin Van Thillo, et al.
Published: (2025-02-01)